Drug news
CHMP recommends approval of Cialis (Eli Lilly) for Benign Prostatic Hyperplasia
The CHMP in the EU has recommended approval of Cialis (tadalafil), from Eli Lilly and Co, for once daily use for the treatment of the signs and symptoms of Benign Prostatic Hyperplasia (BPH). The opinion is now referred for final action to the European Commission, which has the authority to approve medicines for the EU. The Commission usually decides on CHMP recommendations within one to two months. Cialis was approved for Erectile Dysfunction (ED) in the EU in 2002. Cialis for once daily use was approved for the treatment of ED in the EU in 2007. Cialis for once daily use was approved by the FDA in October 2011 for the treatment of the signs and symptoms of BPH. The FDA also approved Cialis for once daily use to treat men who have both Erectile Dysfunction and the signs and symptoms of Benign Prostatic Hyperplasia (ED+BPH).
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins